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Abstract 
Means to overcome tumor hypoxia have been the subject of clinical investigations since the 
1960’s; however these studies have yet to find a treatment which is widely accepted. It has 
been known for nearly a century that hypoxic cells are more resistant to radiotherapy than 
aerobic cells, and tumor hypoxia is a major factor leading to the resistance of tumors to ra-
diation treatment as well as several cytotoxic agents. In this manuscript, the application of 
ultrasound combined with oxygen-carrier microbubbles is demonstrated as a method to 
locally increase dissolved oxygen. Microbubbles can also be imaged by ultrasound, thus 
providing the opportunity for image-guided oxygen delivery. Simulations of gas diffusion and 
microbubble gas exchange show that small amounts (down to 5 vol%) of a low-solubility 
osmotic gas can substantially increase microbubble persistence and therefore production 
rates and stability of oxygen-carrier microbubbles. Simulations also indicate that the lipid shell 
can be engineered with long-chain lipids to increase oxygen payload during in vivo transit. 
Experimental results demonstrate that the application of ultrasound to destroy the mi-
crobubbles significantly enhances the local oxygen release. We propose this technology as an 
application for ultrasound image-guided release of oxygen directly to hypoxic tissue, such as 
tumor sites to enhance radiotherapy. 
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Introduction 
Tumors are often characterized by lowered vas-
cular density, irregular vascular geometry, incon-
sistent oxygen gradients and rheologic effects which 
contribute to hypoxic conditions [1]. It has been 
known for nearly a century that hypoxic cells are 
more resistant to radiotherapy than aerobic cells, and 
tumor hypoxia is a major factor leading to the re-
sistance of tumors to radiation treatment and cyto-
toxic agents [2, 3]. Additionally, tumor hypoxia is 
associated with increased likelihood of regional re-
currence and metastases, and often leads to poor 
treatment outcome and prognosis [2, 4-7]. 
 Means to overcome tumor hypoxia have been 
the subject of clinical investigations since the 1960’s; 
these studies, however, have yet to find a treatment 
that is widely accepted. Technical logistics limit the 
practical use of hyperbaric oxygen delivery, inhaled 
carbogen has been shown to result in vasoconstriction 
which counteracts the desired effect, and nitroimid-
azoles and other radiosensitizers have not gained fa-
vor because of their toxicity and lack of consistent 
effectiveness [8]. Yet scientists believe “there is good 
evidence … that improving clinical outcome by hy-








In a review by Brown and Wilson [9], it was re-
ported that all human tumors have median oxygen 
levels significantly lower than their normal tissue of 
origin. Unlike the normal subcutaneous tissue that 
has a median oxygen partial pressure between 40 and 
60 mmHg, many tumors have an oxygen partial 
pressure on the order of 10 mmHg [9]. Full resistance 
to radiation occurs when the cells are near anoxic, 
with very low oxygen levels of approximately 0.2 
mmHg; however, resistance to radiation begins at 
higher oxygen concentrations of about 20 mmHg [9]. 
Therefore, the oxygen partial pressures between 0.2 
and 20 mmHg can be described as an intermediate 
range of resistance to radiation.  
 A radiation survival curve illustrates the sur-
viving fraction of tumor cells with respect to radiation 
dose, where the effect of oxygen is to reduce the slope 
of this curve. The “oxygen enhancement ratio” (OER) 
is often described as the degree of radiation sensitiza-
tion and refers to the ratio of doses in the absence of 
oxygen and in the presence of oxygen to provide the 
same cell survival. The value for mammalian cells was 
given to be between 2.5 to 3.0. This value includes 
several endpoints including cell killing, mutagenesis, 
and the induction of chromosome aberrations [10]. 
The seemingly low OER value of 2.6 corresponds to 
50% of cells killed under hypoxic conditions as op-
posed to almost 99% of the cells killed under aerobic 
conditions with a radiation dose of 1,000 cGy [11]. 
This information implies that tumor cells with oxygen 
levels in the intermediate range can be re-oxygenated, 
which would result in an increased sensitivity of cells 
to radiation. Additionally, it has been demonstrated 
[12] that hypoxic tumor cells become sensitive for 
radiation even if the oxygen is present less than a 
second before or after exposure to radiation therapy. 
More recent work has correlated low reactive 
oxygen species (ROS) concentrations with radiore-
sistance in cancer stem cells [13]. Pharmacological 
depletion of ROS scavengers in cancer stem cells was 
shown to decrease their clonogenicity and result in 
radiosensitization. An alternative approach may be to 
increase local oxygen concentration, and therefore 
ROS production, in order to improve ioniz-
ing-radiation-induced cell killing of cancer stem cells 
and their tumorigenic progeny. 
 Ultrasound, in conjunction with microbubbles, 
has the unique advantage of being able to provide 
safe, noninvasive and image-guided, site-specific 
treatment. An ultrasound transducer can be used to 
image the local anatomy in order to define the region 
for treatment. Microbubbles are highly echogenic in-
travascular contrast agents that can be used to help 
define the vascular architecture and blood flow pat-
terns in the tumor area [14, 15]. Targeted microbub-
bles can be used to image endothelial epitopes asso-
ciated with neovascularization and inflammation, 
thereby enabling ultrasound molecular imaging 
[16-18]. Ultrasound also applies the required thera-
peutic pulses to the sample volume by focusing on the 
tumor region with imaging guidance for feedback. 
Microbubbles have already been FDA approved in the 
US for contrast agents in echocardiography, and im-
aging microbubbles are used even more extensively in 
Canada, Europe, India and Asia. Therapeutic mi-
crobubbles for oxygen delivery could be made with 
similar characteristics.  
 Although a few prior studies have investigated 
the use of microbubbles for the delivery of oxygen, 
these studies have largely focused on microbubbles to 
be injected into the circulation to increase systemic 
oxygen for anemia [19-23]. Burkard and Van Liew [24] 
proposed that microbubbles containing a heavy gas 
(osmotic agent) could serve as an blood substitute. In 
an animal study by Lundgren et al. [21], it was sug-
gested that an emulsion of dodecafluoropentane 
(DDFP) injected intravascularly combined with oxy-
gen breathing could transfer physiologically signifi-
cant amounts of oxygen in severely anemic rats. Ger-
ber et al. [19] examined the stability of microbubbles 
made with fluorinated phosholipid instead of a 
standard hydrogenated phospholipid shell. They 
suggested that microbubbles could be engineered to 
comprise a shell and gas core to promote a longer in 
vivo half-life and more efficacious systemic delivery. 
To our knowledge, however, the application of ultra-
sound for targeted oxygen delivery to overcome local 
hypoxia has not yet been demonstrated. 
The use of ultrasound in our study as a mecha-
nism for local microbubble fragmentation makes it 
possible for the oxygen to be released from the mi-
crobubbles directly at the tumor site right before or 
even during radiation therapy. In this manner, oxygen 
is released immediately in tumor microvasculature 
rather than slowly and throughout the entire systemic 
circulation, as would be the case with non-ultrasound 
enhanced mechanisms. Hence, we hypothesize that 
ultrasound combined with oxygen delivery mi-
crobubbles can provide a means of greatly enhancing 
the tumor-specific dose of oxygen. Additionally, we 
propose that the already demonstrated contrast en-
hancement capabilities of oxygen microbubbles can be 
used to guide and monitor the ultrasound-mediated 
oxygen release in situ. In this manuscript, we perform 
theoretical calculations to investigate oxygen mi-
crobubble stability and experimentally demonstrate 
the ability of ultrasound to locally enhance oxygen 
concentration through the disruption of oxy-






 Fluorocarbon gases have low aqueous solubility 
and diffusivity, and thus have been used as osmotic 
agents to stabilize oxygen-carrier microbubbles [24, 
25]. We employed a multi-gas microbubble dissolu-
tion model to elucidate the role of the fluorocarbon on 
microbubble stability and oxygen release [26, 27]. The 
model describes the transient change in gas-core con-
tents and microbubble size as a function of the mi-
crobubble shell properties and surrounding gas 
composition. The model includes a coupled set of 
nonlinear differential equations describing the gas 
accumulation, which is coupled to both the mechani-
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∑𝑛𝑖          …(2) 
where i represents a gas species (j ≠ i  to prevent dou-
ble counting), n is the moles of gas in the microbubble 
core, t is time, R is the radius of the microbubble, KH is 
the Henry’s constant, D is the diffusivity of gas in the 
surrounding medium, Ωs is the resistance to gas per-
meation of the lipid shell, σ is the surface tension 
(assumed to be isotropic), PH is the hydrostatic pres-
sure, B is the ideal gas constant, T is the temperature, f  
is the fraction of gas in surrounding bulk medium to 
that at saturation, and Psat is the saturation pressure of 
gas in the surrounding bulk medium. One can esti-
mate the dependence of the gas permeability (Ωs) by 
implementing an energy barrier model, as recently 






(𝜎0−𝜎)              …(3) 
where Ωn  is an empirical constant dependent on the 
lipid encapsulation, a is the collision radius of the gas 
molecule, kB  is the Boltzmann constant, and σo  is the 
surface tension of a gas-liquid interface. Equation 1 is 
used to determine the flux of each gas into the mi-
crobubble over a given time step, and then equation 2 
is used to determine the resulting microbubble radius. 
Numerical solution of the two equations provides a 
theoretical prediction of the microbubble radius-time 
behavior. 
Previous experimental results showed that li-
pid-coated microbubbles experience a dynamic sur-
face tension as they experience growth and compres-
sion during gas exchange [26, 27]. Based on the em-
pirical constitutive developed model by Kwan and 
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𝑅 < 𝑅0 (𝑅𝑒𝑠𝑡𝑖𝑛𝑔)
0 < 𝜎 < 𝜎𝑏𝑟𝑒𝑎𝑘  (𝐸𝑥𝑝𝑎𝑛𝑠𝑖𝑜𝑛)
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       …(4) 
 
where kE is the linear expansion elasticity of the 
lipid monolayer, R0 is the initial radius of the mi-
crobubble, σbreak is the rupture tension of the lipid 
monolayer (~73 mN/m), σEQ is the equilibrium 
spreading tension (~25 mN/m), κE is the domain re-
laxation rate (a measure of domain dissolution) of the 
interface after rupture, Rbreak is the radius at which 
rupture occurs, Rmax is the maximum radius before 
dissolution, σRmax is the tension of the monolayer at 
the maximum radius, and kC is the compression elas-
ticity. This model was derived to explain the re-
sistance towards expansion behavior observed by 
microscopy images of lipid-coated microbubbles un-
dergoing gas exchange [27]. To our knowledge, this 
model most accurately accounts for the highly non-
linear properties of the lipid shell during the relatively 
slow dynamics associated with microbubble dissolu-
tion in vivo. 
Materials and Methods 
Microbubble Formulation 
The lipids 1,2-distearoyl-sn-glycero-3- 
phosphocholine (DSPC) and 1,2-distearoyl-sn- 
glycero-3-phosphoethanolamine-N-[methoxy(polye 
thyleneglycol)-2000] (DSPE-PEG2000) were pur-
chased from Avanti Polar Lipids (Alabaster, AL, 
USA). The buffer solution for the lipids was prepared 
using Tris (Hydroxymethyl) Aminomethane pur-




chased from EMD Chemicals (Gibbstown, NJ, USA). 
The pH of the buffer solution was adjusted to 7.4 us-
ing hydrochloric acid. The lipid composition included 
1.5 mg/mL DSPC in 10 vol. % glycerin (Fisher Scien-
tific, Pittsburgh, PA, USA), 10 vol. % propylene glycol 
(Sigma-Aldrich, St. Louis, MO, USA), and 80 vol. % 
deionized water, with a 9:1 mol:mol ratio of DSPC to 
DSPE-PEG2000. The lipids dissolved in chloroform 
were exposed to nitrogen and degassed for 16 hours 
to evaporate the chloroform. Once the lipids were dry, 
the buffer solution was added to the lipids in a vial. 
The lipid solution was sonicated until a transparent 
and homogeneous mixture was achieved. Vials of 1.5 
mL of the lipid solution were degassed for 5 minutes. 
Microbubble solutions were activated by shaking vi-
als in a Vialmix shaker (Bristol-Myers Squibb Medical 
Imaging Inc., North Billerica, MA, USA) as previously 
described [28]. Concentration and size distribution of 
microbubble suspensions were determined with an 
optical particle counter with a 0.5 μm diameter lower 
detection limit (Accusizer Particle Sizing Systems, 
Santa Barbara, CA, USA). 
 Ultrasound Generation for Bubble Disruption 
A single element 1 MHz unfocused ultrasound 
transducer (Valpey Fisher Corp., Hopkinton, MA, 
USA) was used for transmission. The transducer was 
excited with a 10 cycle sinusoid pulse with pulse rep-
etition frequency of 25 Hz. The pulse was generated 
on an arbitrary wave generator (AWG 2021, Tektro-
nix, Inc., Beaverton, OR, USA) and amplified by an RF 
amplifier (3200 L, ENI, Rochester, NY, USA). A cali-
brated needle hydrophone (Onda Corp., Sunnyvale, 
CA, USA) was used to record acoustic pressure 
measurements. The transducer focus occurred at 6.4 
mm from the transducer face where the acoustic 
pressure was measured to be 1200 kPa peak negative 
pressure. Prior studies have demonstrated that for a 
transducer with a center frequency of 1 MHz, acoustic 
pressures greater than 800 kPa are sufficient to frag-
ment lipid-encapsulated microbubbles [29]. Although 
we chose to use 1 MHz in this study for convenience, 
it is important to note that higher frequencies and 
pressures, such as those regularly used in clinical 
imaging applications, could also be used to fragment 
the microbubbles and release their gas content. 
Dissolved Oxygen Measurements 
For dissolved-oxygen measurement experi-
ments, a small amount of microbubbles was injected 
using a calibrated pipetter (Biohit, Neptune, NJ, USA) 
into 70 mL of deionized water in a glass beaker. A stir 
bar in the beaker was used to gently keep the solution 
mixed during experiments. Prior to bubble addition, 
dissolved oxygen measurements determined between 
45%-60% saturation at room temperature, indicating 
the water was partially saturated. A FOXY-R Oxygen 
Sensor and USB fiber-optic spectrometer (Ocean Op-
tics Inc., Dunedin, FL, USA) was used to measure the 
change in the oxygen concentration during ultra-
sound exposure. The tip of ultrasound transducer was 
immersed into the beaker for ultrasound administra-
tion. All experiments were performed at 22 oC and 1 
atm. 
Simulations 
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Equation 5 was solved at the beginning of each 
time step. The results of equation 5 were used in 
equation 6, which was solved using a minimization 
algorithm in Matlab R2010b (MathWorks, Inc., Natick, 
MA, USA). Table 1 and 2 give the parameters used in 
the simulations. 




Table 1: Gas properties used in modeling microbubble gas 
exchange. 
Gas Properties Oxygen Nitrogen PFB Water 
Vapor 
Diffusivity - [m2/s] x 
109 
3.948 a, b 1.713 a, b 0.4935 b 315.16*  
Henry’s Constant -  
[(g/m3)/Pa] x 104 
2.42 c, d 2 c, d 0.69 b 2.1 * 
Collision Diameter [Å] 0.34 e 0.37 e 0.60 e 0.34 e 
a - [30]; b - [31]; c - [32]; d - [33]; e - [34] 
* – Values estimated from vapor pressure at 25 C 
 
 
Table 2: Lipid shell parameters used in modeling mi-
crobubble gas exchange. 
Lipid Properties DMPC DPPC DSPC DBPC  
Expansion Elasticity - 
[N/m]  
5.0 f 6.0 f 3.6 f 3.4 f  
Domain Relaxation 
Rate - [1/s] 
0.8 f 0.6 f 0.2 f 0.1 f 
Compression Elasticity 
- [N/m] 
0.07 f 0.3 f 0.3 f 0.7 f 
f - [27] 
 
Results 
Fabrication of stable, high-oxygen microbub-
bles 
In initial studies, we attempted to formulate mi-
crobubbles with 100% oxygen [22, 23]. We observed, 
however, that the stability and production yield of the 
microbubbles was insufficient for ultra-
sound-mediated delivery (data not shown). Previous 
research has shown that use of a sparingly soluble 
“trapped species” can significantly enhance emulsion 
stability, presumably owing to Raoult’s law where the 
chemical potential gradient for oxygen to diffuse into 
the microbubble in order to dilute the osmotic agent 
balances the chemical potential gradient for oxygen to 
dissolve out of the microbubble brought on by the 
capillary pressure [35, 36]. We therefore hypothesized 
that the use of the perfluorobutane as a trapped spe-
cies (osmotic agent) would increase the production 
yield and stability of the oxygen microbubbles with-
out significantly affecting the oxygen loading capaci-
ty. To test this, we formulated the microbubbles with 
95% oxygen and 5% perfluorobutane. The average 
microbubble diameter for the resulting oxy-
gen/perfluorobutane mixture was measured to be 
approximately 4 microns, and the average microbub-
ble concentration was on the order of 1010 per mL of 
suspension. 
In order to confirm our experimental findings 
and provide a theoretical basis for the effect of the 
trapped species, we simulated microbubble stability 
using equations 5-6. The simulations predicted the 
dynamics of a newly generated microbubble sub-
merged in a solution saturated with the filling gas 
(95% oxygen and 5% perfluorobutane). The initial 
diameters of the microbubbles were set to 2, 4, 6 and 
10 µm, and the surface tension was set to that of a 
clean gas/water interface (73 mN/m) to simulate a 
newly generated, uncoated microbubble. Figure 1 
shows that the addition of perfluorobutane increased 
the dissolution time (increased stability) by an order 
of magnitude (11-fold) across all of the microbubble 
sizes. As expected, the PFB gas component behaved as 
an insoluble diluent and as a result reduced the over-
all efflux of gas out of the microbubble. Figure 1D 
indicates that the oxygen in the microbubbles quickly 
dissolves, concentrating the remaining PFB in the mi-
crobubble core. Consequently, the now predomi-
nately PFB gas core diffuses slowly, which can be seen 
as a shoulder on the diameter-time curves for the ini-
tially O2:PFB-filled microbubbles (Figure 1B). Alt-
hough these results neglect the effects of forming a 
lipid shell, they demonstrate that the longer residence 
time of the newly generated perfluorobu-
tane-containing microbubbles allow for a significant 
increase in time for lipid adsorption, monolayer for-
mation and stabilization through reduction in surface 
tension. Ultimately, the microbubble will equilibrate 
with the bulk concentration once Laplace pressure is 
removed [26, 27, 37-39]. 
Ultrasound-Targeted Oxygen Release 
 For the first part of the experiment, a fixed 
volume of 300 µL of microbubbles (95% O2 and 5% 
PFB) was injected into 70 mL of partially-saturated 
deionized water. The concentration of dissolved ox-
ygen (given as percentage) was measured after 60, 120 
and 240 seconds with and without ultrasound expo-
sure. The values for the control group were obtained 
with microbubbles with the same mean population 
and size distribution without using the ultrasound. 
The rapid change in dissolved oxygen concentration 
was directly related to the application of ultrasound 
and increased with the duration of ultrasound expo-
sure. As seen in Figure 2, after 240 seconds of ultra-
sound transmission, the change in the oxygen satura-
tion was more than 3 times higher than the change in 
the oxygen when the solution was exposed to 60 sec-
onds of ultrasound.  
 





Figure 1. Normalized diameter-time curves of uncoated, newly generated A) pure oxygen and B) 95% oxygen and 5% perfluorobutane 
microbubbles. Gas content over time of the initially generated C) pure oxygen and D) 95% oxygen and 5% perfluorobutane microbubbles. 




Figure 2. Effect of ultrasound exposure duration on oxygen 
release from microbubbles. Shown is the experimentally measured 
percent change in oxygen concentration following both ultrasound 
treated and untreated 300-µL injection of 1010 microbubbles/mL 
into 70-mL of water. 
 
The volume of bubbles added to the 70 mL of DI 
water was increased in steps of 100 µl, from 100 to 300 
µl. The dissolved oxygen concentration was measured 
after 60 and 120 seconds of ultrasound exposure. As in 
the previous part of the experiment, the control group 
was used to form a baseline with the same amount of 
microbubbles, but excluding ultrasound exposure. 
Figure 3 shows the percent change in oxygen satura-
tion as a function of microbubble concentration in 70 
mL of partially saturated water, with and without 
ultrasound. Using the microbubble suspension in 
conjunction with ultrasound, we were able to achieve 
a significant (p < 0.05) increase in the dissolved oxy-
gen content. The increase in percent oxygen satura-
tion was 6%, 10% and 15% when 100 µL, 200 µL and 
300 µL of microbubbles were infused in the water. 
Dissolved oxygen concentration was calculated 
as a function of bubble concentration and mean bub-
ble size at 22 oC and 760 mmHg total atmospheric 
pressure (see Appendix). At body temperature (37 
oC), the gas solubilities and diffusivities are slightly 
higher, and thus we expect a corresponding increase 
in the rate of gas exchange and oxygen release; how-
ever, this is not expected to change the conclusions 
drawn from this study. For an increase in temperature 
to Calculated values for dissolved oxygen concentra-
tion were compared with the measured values of 
percent dissolved oxygen saturation for increased 
volumes of microbubbles added to the solution as 
shown in Figure 4. The calculations were made for 
microbubbles between 100 and 300 microliters with 20 
microliter intervals. The values for both calculated 
and experimental oxygen saturation were in agree-
ment. 






Figure 3. Percent change in oxygen saturation using microbub-
bles filled with oxygen and perfluorocarbon with and without 
ultrasound. The experimental values were obtained using 100, 
200, and 300 µL of microbubbles. The asterisk (*) represents a 
one-tailed t-test p value below 0.05. 
 
 
Figure 4. Percent change in oxygen saturation using microbub-
bles filled with oxygen and perfluorocarbon and calculated change 
in percent oxygen saturation. The predicted values were deter-
mined based on a 4-µm diameter bubble population with a con-
centration of 1010 bubbles/mL. 
 
 
To demonstrate that the increase in oxygen sat-
uration was primarily due to the activation of oxy-
gen-PFC microbubble dissolution via ultrasound, the 
above study was also performed on microbubbles 
filled with nitrogen. As in the first part of the experi-
ment, 300 µl of nitrogen filled microbubbles were in-
jected into 70 mL of DI water in a glass beaker. Dis-
solved oxygen concentration was measured after 60, 
120 and 240 seconds of ultrasound exposure. The 
values for the control group, i.e., microbubbles not 
treated with ultrasound, were also obtained at the 
same time intervals. The increase in dissolved oxygen 
concentration was evident when we compared mi-
crobubbles filled with oxygen and PFC with mi-
crobubbles filled only with nitrogen. Figure 5 shows 
that microbubbles filled with nitrogen instead of ox-




Figure 5. Comparison of mean percent change in oxygen satu-
ration of 300 microliters of microbubbles filled with either pure 
nitrogen or with an oxygen and perfluorocarbon mixture. The 
time of ultrasound exposure was 240 s. The asterisk (*) represents 
a one-tailed t-test p value below 0.05. Nitrogen-filled microbub-
bles did not increase oxygen saturation significantly. 
 
Simulations on microbubble persistence and 
oxygen payload during gas exchange 
Gas-exchange simulations of a li-
pid-encapsulated, 4-µm diameter microbubble sud-
denly submerged in an air-saturated solution were 
performed in order to mimic the experimental condi-
tions. Results are shown in Figure 6 for the normal-
ized diameter and the gas content in the microbubble. 
The lower partial pressure of oxygen in the sur-
rounding milieu drives the efflux of oxygen, and the 
microbubble initially shrinks over the first one to ten 
seconds owing to the more rapid permeation of oxy-
gen in water compared to nitrogen and the other 
gases. However, the partial pressure of nitrogen in the 
surrounding medium is higher, which drives its in-
flux into the microbubble, and the radius increases 
back to the initial diameter. Nitrogen essentially dis-
places the excess oxygen and the microbubble rapidly 
becomes either an air bubble or a nitrogen bubble 
with the partial pressures of the contents equilibrating 
with the surrounding medium. Membrane elasticity 
prevents any expansion beyond the initial diameter. 
As a result, the final microbubble diameter is ap-
proximately equal to the initial diameter. 
We also simulated the effect of the lipid shell 
composition on the transient oxygen gas payload. 
Interestingly, the interfacial mechanics of the mono-




layer did not play a significant role; the microbubble 
did not present any significant growth and therefore 
did not leave the linear elastic regime of the mono-
layer. As a result, the shell composition did not in-
fluence the final microbubble size or core composi-
tion. The addition of methylene groups to the hy-
drophobic tail did however increase the overall time 
for gas exchange to take place. According to these 
simulations, this increase in duration for gas exchange 
was primarily due to the decrease in gas shell per-
meability for the larger acyl-chain lipids. For example, 
complete gas exchange in an air-saturated solution for 
DSPC- and DBPC-coated microbubbles was estimated 
to take 6 times longer than DMPC- and DPPC-coated 
microbubbles. Similarly, intravenously injected 
DBPC-coated oxygen microbubbles will deposit 
~99.9% of their payload in ~15 seconds compared to 
~3 seconds for DMPC-coated microbubbles. Our pre-
dictions imply that the use of longer acyl-chain lipid 
encapsulations significantly improve the oxygen 








Figure 6. Simulations results for a 4-µm diameter microbubble coated with DMPC, DPPC, DSPC, or DBPC that initially is comprised of 
95% oxygen and 5% perfluorobutane suddenly immersed in A,C) an air-saturated medium or B,D) a nitrogen-saturated medium at 22 oC 
and 1 atm pressure. A-B) the diameter is normalized to the initial diameter and plotted as a function of time. C-D) the gas contents inside 
the microbubble over time. E-F) the oxygen content inside the microbubble over time. 
 




The simulations also predicted that each 4-µm 
diameter bubble releases ~1 fmol of oxygen upon 
contact with the air-saturated medium, and it retains 
~0.25 fmol of oxygen in the gas core. The simulation 
considers only a single microbubble, and not the en-
semble where the partial pressure of oxygen in the 
bulk medium would increase as the microbubbles 
release their excess oxygen. For the experimental 
conditions, ~3x109 microbubbles were injected into a 
70 mL volume of water. The initial oxygen concentra-
tion for the air-saturated medium is estimated to be 
285 nmol/mL based on Henry’s constant shown in 
Table 1. According to the results of our simulation, we 
predict that the 300-µL microbubble injection would 
raise the total oxygen concentration to 330 nmol/mL 
from the combined oxygen released from the mi-
crobubbles owing to natural diffusion (43 nmol/mL) 
and to dissolved oxygen present in the suspension 
medium (2 nmol/mL). This corresponds to a 16% 
increase in dissolved oxygen by natural diffusion, 
which is higher than the measured 5% increase after 
60 s of ultrasound (Fig. 2). The discrepancy between 
the theoretical and measured values for the increase in 
oxygen concentration may be due to the combined 
effects of the rise in bulk concentration of oxygen and 
the retardation of gas diffusion through the shell [40]. 
If all of the microbubbles were destroyed by ultra-
sound, then the oxygen content would be expected to 
rise by 19%, which is more than the 15% increase ob-
served experimentally after 240 s of ultrasound (Fig. 
2). This difference may be due to incomplete mi-
crobubble destruction, for microbubbles that were not 
mixed into the region of ultrasound exposure, and the 
gradual loss of oxygen to the atmosphere.  
Discussion 
 If cells in a tumor have mean oxygen partial 
pressure of approximately 3 mmHg (as estimated for 
pancreatic, cervical and prostate cancer cells [9], and if 
the oxygen partial pressure is increased by 30 mmHg 
via sufficient microbubbles delivered to those tumor 
cells and bursting the oxygen filled microbubbles by 
an ultrasound system, the OER will improve almost 
by a factor of 0.65. This OER factor of 0.65 would 
mean a significant increase in the percentage of ther-
apeutic efficiency according to the radiation survival 
curve. To convert the percent change in oxygen satu-
ration to oxygen partial pressure (pO2) we used the 
following formula: 
Oxygen Saturation (%) = [pO2/(0.2094 x 750mmHg)] x 100 
where 0.2094 is the mole fraction of oxygen in the 
atmosphere and 750 mmHg is the absolute pressure. 
Ultimately, the amount of oxygen bubbles required to 
be injected to reach a desired oxygen partial pressure 
depends on the tumor size (e.g., measured by ultra-
sound) and its initial oxygen partial pressure (e.g., 
measured by electrodes and spectroscopic tech-
niques). For example, to cause an increase of 42 
mmHg of oxygen partial pressure in a tumor with a 
volume of 1 mL, which corresponds to approximately 
27% increase in oxygen saturation, 1 mL of mi-
crobubbles filled with oxygen mixture would need to 
be injected intravascularly assuming 1% of mi-
crobubbles would be destroyed in the tumor itself by 
an ultrasound system. The actual number of mi-
crobubbles destroyed in a tumor depends again on 
the tumor size, as well as the acoustic focus and cir-
culation time for the microbubbles. However, for our 
assumption we consider a liver tumor that encom-
passes approximately 10% of the liver volume,[41] 
and we assume that the liver receives about 13% of 
circulatory blood flow.[42] Currently available mi-
crobubbles for imaging persist for several passes 
through the circulation,[43] so it is reasonable to ex-
pect that oxygen delivery bubbles could be designed 
similarly. 
 In order to develop a clinically viable mi-
crobubble oxygen delivery agent, one must be able to 
produce microbubbles in high yield. Early observa-
tions showed that pure oxygen microbubbles could be 
generated, but resulted in low yields and were gener-
ally not stable. The addition of perfluorobutane was 
shown to increase both the yield and stability of these 
oxygen microbubbles. The simulations showed that 
this increase in yield may have been an effect of the 
slower efflux of perfluorobutane gas compared to 
oxygen. This reduced efflux of gas increased the dis-
solution time by approximately 11 fold. As a result, 
there would be more time for lipids in the surround-
ing microbubble generating solution to adsorb onto 
the interface, decreasing the surface tension, halting 
the dissolution, and ultimately increasing the total 
yield of newly formed microbubbles.  
 Finally, the effect of administration of large 
quantities of microbubbles intravascularly in humans 
is unknown, and microbubbles are not yet approved 
for clinical therapeutics applications. The recom-
mended dose of Definity, a microbubble used for 
contrast ultrasound imaging, is 10 microLiters per kg. 
The maximum dose here (300 microLiters into 70 mL 
of water) was 33 fold greater than this clinically uti-
lized dose (assuming 75mL of blood per kg). Howev-
er, studies in rats have shown that doses 20 times that 
what is recommended for clinical imaging do not re-
sult in measurable changes in hepatic function, where 
much of the clearance occurs,[44] and there have been 
no adverse effects in repeated toxicology studies in 




rats and dogs with doses corresponding to 50 to 250 
times the expected imaging dose in humans, respec-
tively.[45] 
 In these experimental studies, we demonstrate 
that oxygen-carrier microbubbles can increase the 
oxygen saturation by diffusion and through ultra-
sound mediation. Without ultrasound, we showed 
that there was a marginal increase in oxygen satura-
tion. Combining ultrasound and oxygen-carrier mi-
crobubbles, we can achieve an increase in local oxy-
gen saturation that may be clinically relevant. Our 
results demonstrated that within 240 seconds, we can 
change the local oxygen concentration by a factor of 3 
fold greater than that achieved in the same amount of 
time without ultrasound.  
 In our studies, we hypothesize that the ¼” ele-
ment ultrasound transducer, which only insonified a 
small percentage of our 70 mL sample volume, was 
the reason that complete microbubble destruction 
required 240 seconds. In-vivo, a phased array ultra-
sound system would be able to sonicate a tumor 
volume much more rapidly – releasing the majority of 
oxygen carriers almost instantaneously. The combi-
nation of the imaging capabilities of phased array 
ultrasound systems will additionally allow registra-
tion of the area to be treated. 
 In the in-vivo case, however, the limiting factor 
would likely be the amount of carriers that are present 
in the tumor vasculature. Administration of the oxy-
gen carrier microbubbles in a feeder artery close to the 
tumor site in conjunction with ultrasound would 
greatly enhance local delivery, in contrast to periph-
eral vein injection typically used with the administra-
tion of microbubble-type contrast agents.  
 Ultrasound is a widespread, safe, portable, and 
relatively inexpensive modality. Ultrasound can be 
used to not only image the tumor target, but also to 
apply energy to mediate the therapeutic effect of ox-
ygen delivery. A system to apply ultrasound during 
radiotherapy is technologically feasible [46]. Based on 
our initial studies, the ultrasound parameters to me-
diate tumor oxygenation through acoustically-active 
oxygen delivery vehicles will likely be within the FDA 
limits already approved for clinical ultrasound imag-
ing. 
Conclusions 
 We give an explanation for the high yield and 
stability of oxygen-perfluorobutane microbubbles and 
demonstrate preliminary results of the first study of 
oxygen delivery via stabilized microbubbles in con-
junction with ultrasound. We also hypothesize that 
this method will provide a minimally-invasive tech-
nology which will allow a physician to locally deliver 
oxygen to tumor tissue during radiation treatment 
and enhance tumor radiation sensitivity. This novel 
approach has the potential to substantially improve 
therapeutic treatment for cancer by both increasing 
tumor response to radiation, and reducing the radia-
tion dose required for a therapeutic effect.  
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Appendix 
 The dissolved oxygen concentration in water is 
8.8 mg/L at a temperature of 22 degrees Celsius and 
an atmospheric pressure of 760 mmHg. The solubility 
of oxygen changes with total atmospheric pressure 
and the temperature as described by Henry’s Law. 
Our experimental conditions stayed the same during 
the oxygen saturation measurements at a temperature 
of 22 degrees Celsius and atmospheric pressure of 760 
mmHg. The number of microbubbles per milliliter of 
microbubble solution and the average size of mi-
crobubbles were used to calculate the total volume of 
oxygen contained in the microbubbles infused into 
the water using the following equation: 




where, 𝑉𝑂2  is the volume of oxygen in solution, Cbubble  
is the number of microbubbles per mL, and r is the 
average radius of the microbubbles. 
